Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Masa Lasica"'
Autor:
Simon Fifer, Jenni Godsell, Stephen Opat, Nada Hamad, Masa Lasica, Cecily Forsyth, Louisa Morand, Erica Smeaton, Sharon Winton, Andrea Puig, Marija McGeachie
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Listening to patient voices is critical, in terms of how people experience their condition as well as their treatment preferences. This research explored the patient journey, therapy attributes and goals among treatment experience
Externí odkaz:
https://doaj.org/article/393844fe1e9649d6889941648fb36c92
Autor:
Thi H. O. Nguyen, Chhay Lim, Masa Lasica, Ashley Whitechurch, Surekha Tennakoon, Natalie R. Saunders, Lilith F. Allen, Louise C. Rowntree, Brendon Y. Chua, Lukasz Kedzierski, Hyon‐Xhi Tan, Adam K. Wheatley, Stephen J. Kent, Theo Karapanagiotidis, Suellen Nicholson, Deborah A. Williamson, Monica A. Slavin, Constantine S. Tam, Katherine Kedzierska, Benjamin W. Teh
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 216-220 (2023)
Abstract Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to
Externí odkaz:
https://doaj.org/article/745a4564cb6c465c9f3c734f9e73a326
Autor:
Sikander Ailawadhi, Zi Chen, Bo Huang, Aneel Paulus, Mary C. Collins, Lei (Tommy) Fu, Mingyu Li, Mohammad Ahmad, Lichuang Men, Hengbang Wang, Matthew S. Davids, Eric Liang, Divya J. Mekala, Zhicong He, Masa Lasica, Costas K. Yannakou, Ricardo Parrondo, Laura Glass, Dajun Yang, Asher Chanan-Khan, Yifan Zhai
Publikováno v:
Clinical Cancer Research. :OF1-OF9
Purpose: This global phase I trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell lymphoma 2 (BCL-2) inhibitor, in patients with relapsed or refract
Autor:
Yifan Zhai, Asher Chanan-Khan, Dajun Yang, Laura Glass, Ricardo Parrondo, Costas K. Yannakou, Masa Lasica, Zhicong He, Divya J. Mekala, Eric Liang, Matthew S. Davids, Hengbang Wang, Lichuang Men, Mohammad Ahmad, Mingyu Li, Lei (Tommy) Fu, Mary C. Collins, Aneel Paulus, Bo Huang, Zi Chen, Sikander Ailawadhi
These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1821335217cf53f57ba6d9a948803a00
https://doi.org/10.1158/1078-0432.22841378.v1
https://doi.org/10.1158/1078-0432.22841378.v1
Autor:
Yifan Zhai, Asher Chanan-Khan, Dajun Yang, Laura Glass, Ricardo Parrondo, Costas K. Yannakou, Masa Lasica, Zhicong He, Divya J. Mekala, Eric Liang, Matthew S. Davids, Hengbang Wang, Lichuang Men, Mohammad Ahmad, Mingyu Li, Lei (Tommy) Fu, Mary C. Collins, Aneel Paulus, Bo Huang, Zi Chen, Sikander Ailawadhi
Summary of BH3 profiling for PBMC samples collected at baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::875185de9f18254bdd2b7da2234764bc
https://doi.org/10.1158/1078-0432.22841372
https://doi.org/10.1158/1078-0432.22841372
Autor:
Yifan Zhai, Asher Chanan-Khan, Dajun Yang, Laura Glass, Ricardo Parrondo, Costas K. Yannakou, Masa Lasica, Zhicong He, Divya J. Mekala, Eric Liang, Matthew S. Davids, Hengbang Wang, Lichuang Men, Mohammad Ahmad, Mingyu Li, Lei (Tommy) Fu, Mary C. Collins, Aneel Paulus, Bo Huang, Zi Chen, Sikander Ailawadhi
Purpose:This global phase I trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell lymphoma 2 (BCL-2) inhibitor, in patients with relapsed or refracto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::873c81aecb29906a1ebbbc2642b38af6
https://doi.org/10.1158/1078-0432.c.6649142
https://doi.org/10.1158/1078-0432.c.6649142
Autor:
Masa Lasica, Mary Ann Anderson
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 6, p 463 (2021)
Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored, it has changed the therapeutic landscape in haematolo
Externí odkaz:
https://doaj.org/article/4958f57ed93c43d68f9bb41427352137
Autor:
Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam
Publikováno v:
Blood. 140:9325-9327
Autor:
Chan Y. Cheah, Constantine S. Tam, Masa Lasica, Emma Verner, Peter J. Browett, Mary Ann Anderson, James Hilger, Yiqian Fang, David Simpson, Stephen Opat
Publikováno v:
Blood. 140:2321-2323
Autor:
Constantine S. Tam, Masa Lasica
Publikováno v:
Hematology/Oncology Clinics of North America. 35:761-773
Bruton tyrosine kinase inhibitors have indisputably transformed the treatment landscape of chronic lymphocytic leukemia, but require continuous therapy to maintain response. This places emphasis on their unique toxicity profile and potential loss of